JP2014512182A - ワクチンの免疫原性を改善する方法 - Google Patents

ワクチンの免疫原性を改善する方法 Download PDF

Info

Publication number
JP2014512182A
JP2014512182A JP2014503958A JP2014503958A JP2014512182A JP 2014512182 A JP2014512182 A JP 2014512182A JP 2014503958 A JP2014503958 A JP 2014503958A JP 2014503958 A JP2014503958 A JP 2014503958A JP 2014512182 A JP2014512182 A JP 2014512182A
Authority
JP
Japan
Prior art keywords
antigen
antibody
epitope
compound
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014503958A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014512182A5 (enExample
Inventor
ゲイル ビショップ，
ブッシュ トニー ヴァンデン，
Original Assignee
ユニバーシティー オブ アイオワ リサーチ ファウンデーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニバーシティー オブ アイオワ リサーチ ファウンデーション filed Critical ユニバーシティー オブ アイオワ リサーチ ファウンデーション
Publication of JP2014512182A publication Critical patent/JP2014512182A/ja
Publication of JP2014512182A5 publication Critical patent/JP2014512182A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/13—Poliovirus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6012—Haptens, e.g. di- or trinitrophenyl (DNP, TNP)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32041—Use of virus, viral particle or viral elements as a vector
    • C12N2770/32042—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2014503958A 2011-04-04 2012-04-04 ワクチンの免疫原性を改善する方法 Pending JP2014512182A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161471553P 2011-04-04 2011-04-04
US61/471,553 2011-04-04
PCT/US2012/032190 WO2012138774A2 (en) 2011-04-04 2012-04-04 Methods of improving vaccine immunogenicity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017073558A Division JP2017158556A (ja) 2011-04-04 2017-04-03 ワクチンの免疫原性を改善する方法

Publications (2)

Publication Number Publication Date
JP2014512182A true JP2014512182A (ja) 2014-05-22
JP2014512182A5 JP2014512182A5 (enExample) 2015-05-14

Family

ID=46969796

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014503958A Pending JP2014512182A (ja) 2011-04-04 2012-04-04 ワクチンの免疫原性を改善する方法
JP2017073558A Pending JP2017158556A (ja) 2011-04-04 2017-04-03 ワクチンの免疫原性を改善する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017073558A Pending JP2017158556A (ja) 2011-04-04 2017-04-03 ワクチンの免疫原性を改善する方法

Country Status (9)

Country Link
US (1) US10059746B2 (enExample)
EP (1) EP2694102A4 (enExample)
JP (2) JP2014512182A (enExample)
KR (1) KR20140027211A (enExample)
CN (1) CN103826657A (enExample)
AU (2) AU2012240231B2 (enExample)
CA (1) CA2834734A1 (enExample)
MX (1) MX356426B (enExample)
WO (1) WO2012138774A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018058812A (ja) * 2016-06-01 2018-04-12 パナソニックＩｐマネジメント株式会社 インフルエンザウィルス核内蛋白質に結合する抗体、複合体、それを用いた検出装置及び検出方法

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014120941A1 (en) 2013-02-01 2014-08-07 University Of Iowa Research Foundation Tumor vaccines and methods of use thereof
AR095425A1 (es) 2013-03-15 2015-10-14 Glaxosmithkline Biologicals Sa Vacuna, uso y procedimiento para prevenir una infección por picornavirus
WO2017118702A1 (en) * 2016-01-08 2017-07-13 Vaccibody As Neoepitope rna cancer vaccine
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
EP3927372A4 (en) * 2019-02-21 2023-01-25 Centivax, Inc. OPTIMIZED VACCINE COMPOSITIONS AND METHODS OF PRODUCTION

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5071651A (en) * 1986-09-03 1991-12-10 University Of Saskatchewan Rotavirus nucleocapsid protein VP6 as a carrier in vaccine compositions
WO1992014489A1 (en) * 1991-02-14 1992-09-03 Repligen Corporation Poliovirus-based vaccines
US6221664B1 (en) * 1997-02-26 2001-04-24 Shanghai Medical University Composite vaccine which contains antigen, antibody and recombinant DNA and its preparing method
US20070026502A1 (en) * 1994-04-28 2007-02-01 Matti Sallberg Specificity exchangers that redirect antibodies to a pathogen
WO2007052238A2 (en) * 2005-11-07 2007-05-10 University Of Pretoria Chimeric antigens and vaccines
US20080090225A1 (en) * 2006-06-16 2008-04-17 Kirkegaard Karla A Methods of identifying anti-viral agents
US20080311147A1 (en) * 2004-04-19 2008-12-18 Thomas Jeffeson University Rhabdoviral N-Fusion Proteins as Carrier for Foreign Antigens
US20080311135A1 (en) * 2007-05-22 2008-12-18 Baylor College Of Medicine Immune complex vaccination as a strategy to enhance immunity in the elderly and other immune compromised populations
US20090324630A1 (en) * 2008-04-21 2009-12-31 Jensen Michael C Fusion multiviral chimeric antigen

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US5204096A (en) 1984-03-07 1993-04-20 New York Blood Center, Inc. Pre-S gene coded peptide hepatitis B immunogens, vaccines, diagnostics, and synthetic lipid vesicle carriers
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
ES2284161T3 (es) 1990-01-12 2007-11-01 Amgen Fremont Inc. Generacion de anticuerpos xenogenicos.
CA2109602C (en) 1990-07-10 2002-10-01 Gregory P. Winter Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0605522B1 (en) 1991-09-23 1999-06-23 Medical Research Council Methods for the production of humanized antibodies
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
PT1696031E (pt) 1991-12-02 2010-06-25 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
AU3328493A (en) 1991-12-17 1993-07-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
AU685047B2 (en) * 1992-02-11 1998-01-15 Henry M. Jackson Foundation For The Advancement Of Military Medicine Dual carrier immunogenic construct
JP3507073B2 (ja) 1992-03-24 2004-03-15 ケンブリッジ アンティボディー テクノロジー リミティド 特異的結合対の成員の製造方法
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
CA2125344A1 (en) * 1993-07-01 1995-01-02 Casey D. Morrow Encapsidated recombinant poliovirus nucleic acid and methods of making and using same
WO1995015388A1 (en) 1993-12-03 1995-06-08 Medical Research Council Recombinant binding proteins and peptides
US6660842B1 (en) * 1994-04-28 2003-12-09 Tripep Ab Ligand/receptor specificity exchangers that redirect antibodies to receptors on a pathogen
CA2194907A1 (en) 1994-07-13 1996-02-01 Kouji Matsushima Reshaped human antibody against human interleukin-8
EP0822830B1 (en) 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6232082B1 (en) 1998-12-01 2001-05-15 Nabi Hapten-carrier conjugates for treating and preventing nicotine addiction
US20020131953A1 (en) 2001-03-14 2002-09-19 Ut Southwestern Medical Center In situ langerhans cell vaccine
FR2827605B1 (fr) 2001-07-20 2004-07-16 Pf Medicament Nouveaux peptides derives de la proteine g du vrs et leur utilisation dans un vaccin
KR101228376B1 (ko) 2002-07-18 2013-01-31 사이토스 바이오테크놀로지 아게 합텐-캐리어 컨쥬게이트 및 그의 용도
CA2548180C (en) 2003-12-04 2014-02-04 Vaccinex, Inc. Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cells
US7078179B2 (en) 2004-05-04 2006-07-18 Newlink Genetics Corporation Selectable gene marker system based on expression of N-acetyllactosaminide 3-α galactosyltransferase
EP1797173B1 (en) 2004-10-08 2014-05-14 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Modulation of replicative fitness by using less frequently used synonymous codons
GB0428394D0 (en) 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
AU2006235364A1 (en) * 2005-04-08 2006-10-19 Marina Biotech, Inc. RNAi therapeutic for respiratory virus infection
WO2008118487A2 (en) * 2007-03-26 2008-10-02 University Of Massachusetts Medical School Compositions and methods for incresing immunogenicity of glycoprotein vaccines
EP2223934B1 (en) 2007-11-14 2012-10-03 Institute Of Microbiology, Chinese Academy Of Sciences Polypeptides for inhibiting influenza virus infection
WO2011041691A1 (en) 2009-10-02 2011-04-07 University Of Iowa Research Foundation Methods of improving vaccine immunogenicity

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5071651A (en) * 1986-09-03 1991-12-10 University Of Saskatchewan Rotavirus nucleocapsid protein VP6 as a carrier in vaccine compositions
WO1992014489A1 (en) * 1991-02-14 1992-09-03 Repligen Corporation Poliovirus-based vaccines
US20070026502A1 (en) * 1994-04-28 2007-02-01 Matti Sallberg Specificity exchangers that redirect antibodies to a pathogen
US6221664B1 (en) * 1997-02-26 2001-04-24 Shanghai Medical University Composite vaccine which contains antigen, antibody and recombinant DNA and its preparing method
US20080311147A1 (en) * 2004-04-19 2008-12-18 Thomas Jeffeson University Rhabdoviral N-Fusion Proteins as Carrier for Foreign Antigens
WO2007052238A2 (en) * 2005-11-07 2007-05-10 University Of Pretoria Chimeric antigens and vaccines
US20080090225A1 (en) * 2006-06-16 2008-04-17 Kirkegaard Karla A Methods of identifying anti-viral agents
US20080311135A1 (en) * 2007-05-22 2008-12-18 Baylor College Of Medicine Immune complex vaccination as a strategy to enhance immunity in the elderly and other immune compromised populations
US20090324630A1 (en) * 2008-04-21 2009-12-31 Jensen Michael C Fusion multiviral chimeric antigen

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
BIOCHEM. BIOPHYS. RES. COMMUN., vol. 387, no. 1, JPN6016000875, 11 September 2009 (2009-09-11), pages 180 - 185, ISSN: 0003601642 *
BIOCHIMIE, vol. 70, no. 8, JPN6016000873, August 1988 (1988-08-01), pages 1065 - 73, ISSN: 0003601639 *
CLIN. DIAGN. LAB. IMMUNOL., vol. 1, no. 3, JPN6016000870, May 1994 (1994-05-01), pages 336 - 341, ISSN: 0003601636 *
INFECTION AND IMMUNITY, 1991年, vol. 59, no. 10, JPN6016046383, pages 3504 - 3510, ISSN: 0003601644 *
INFECTION AND IMMUNITY, 2005年, vol. 73, no. 2, JPN6017026532, pages 671 - 678, ISSN: 0003601646 *
J. GEN. VIROL., vol. 70, no. 9, JPN6016000871, September 1989 (1989-09-01), pages 2475 - 2479, ISSN: 0003601637 *
PLOS ONE, vol. Vol.5, No.3, e9812, JPN6016000876, 23 March 2010 (2010-03-23), pages 1 - 11, ISSN: 0003601640 *
PROC. NATL. ACAD. SCI. U S A., vol. 82, no. 6, JPN6016000874, March 1985 (1985-03-01), pages 1785 - 1789, ISSN: 0003601641 *
THE LANCET, 1989年, vol. December 16, JPN6016046381, pages 1415 - 1418, ISSN: 0003601643 *
VACCINE, 1993年, vol. Vol.11, Suppl.1, JPN6016046386, pages 46 - 51, ISSN: 0003601645 *
VACCINE, vol. 14, no. 13, JPN6016000872, September 1996 (1996-09-01), pages 1239 - 1242, ISSN: 0003601638 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018058812A (ja) * 2016-06-01 2018-04-12 パナソニックＩｐマネジメント株式会社 インフルエンザウィルス核内蛋白質に結合する抗体、複合体、それを用いた検出装置及び検出方法

Also Published As

Publication number Publication date
WO2012138774A3 (en) 2014-02-27
NZ617303A (en) 2016-07-29
MX356426B (es) 2018-05-29
AU2017218957A1 (en) 2017-10-19
JP2017158556A (ja) 2017-09-14
CN103826657A (zh) 2014-05-28
US20140134204A1 (en) 2014-05-15
EP2694102A2 (en) 2014-02-12
AU2012240231B2 (en) 2017-05-25
EP2694102A4 (en) 2015-03-04
KR20140027211A (ko) 2014-03-06
US10059746B2 (en) 2018-08-28
AU2012240231A1 (en) 2013-11-14
CA2834734A1 (en) 2012-10-11
WO2012138774A2 (en) 2012-10-11
MX2013011689A (es) 2014-07-14

Similar Documents

Publication Publication Date Title
JP7194104B2 (ja) 抗ｔｌ１ａモノクローナル抗体の中和
JP2017158556A (ja) ワクチンの免疫原性を改善する方法
SA96170384B1 (ar) وطرق تحضيرها واستخداماتها العلاجية (rsv) الاجسام المضادة المعادلة البشرية احادية النسيلة ذات الالفة العالية المختصة ببروتين - ف للفيروس المخلوي التنفسي
TW201100097A (en) Antigen presenting cell targeted vaccines
BR122020023349B1 (pt) Anticorpo monoclonal, linha de célula de hibridoma, kit e uso do anticorpo monoclonal ou um fragmento de ligação ao antígeno do mesmo
US11666645B2 (en) CD200 inhibitors and methods of use thereof
JP6877143B2 (ja) インフルエンザワクチンおよび治療
CN104136039A (zh) 靶向交叉呈递的树突状细胞的疫苗体
JP2023528017A (ja) 重症急性呼吸器症候群コロナウイルス２（ｓａｒｓ－ｃｏｖ－２）ポリペプチドおよびワクチン目的でのその使用
AU2016225926A1 (en) Methods of improving vaccine immunogenicity
KR20020073149A (ko) 핵산 백신접종
US20190321459A1 (en) Universal mammalian influenza vaccine
NZ617303B2 (en) Methods of improving vaccine immunogenicity
US10092635B2 (en) Tumor vaccines and methods of use thereof
CA3004048C (en) Cd200 inhibitors and methods of use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150326

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150326

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160113

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160412

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160610

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160713

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20161202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170403

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20170512

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20170714